In­cyte flips Chi­na rights of Macro­Gen­ic­s' PD-1 to an am­bi­tious Zai Lab keen on leapfrog­ging pi­o­neers with com­bos

Amid the pro­lif­er­a­tion of check­point in­hibitors in Chi­na, Zai Lab is bring­ing in one more PD-1 agent in a move to in­stall what has be­come an es­sen­tial part of any im­muno-on­col­o­gy pipeline.

Orig­i­nal­ly de­vel­oped by Macro­Gen­ics and now con­trolled by In­cyte, IN­CM­GA0012 is in Zai Lab’s view a glob­al­ly com­pet­i­tive as­set that can stand as both a monother­a­py and com­bi­na­tion in­gre­di­ent.

“The mol­e­c­u­lar pro­file is quite sim­i­lar to Keytru­da and Op­di­vo,” said Yongjiang Hei, Zai Lab’s CSO in on­col­o­gy, on an in­vestor call.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER